Evidence map›Paper›PMID 35346293›Full record

ArticleMolecular neurodegeneration2022

Culture shock: microglial heterogeneity, activation, and disrupted single-cell microglial networks in vitro.

Mika P Cadiz, Tanner D Jensen, Jonathon P Sens, Kuixi Zhu, Won-Min Song, Bin Zhang, Mark Ebbert, Rui Chang, John D Fryer

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Microglia extract neuronal proteolytic organelles via skoupocytosis.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Mika P Cadiz *Department of Neuroscience, Mayo Clinic, Scottsdale, AZ, 85259, USA.
Tanner D Jensen *Department of Neuroscience, Mayo Clinic, Scottsdale, AZ, 85259, USA.
Jonathon P Sens *Department of Neuroscience, Mayo Clinic, Scottsdale, AZ, 85259, USA.
Kuixi ZhuDepartment of Neurology, University of Arizona, Tucson, AZ, 85721, USA.
Won-Min SongDepartment of Genetics & Genomic Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Bin ZhangDepartment of Genetics & Genomic Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Mark EbbertSanders-Brown Center on Aging, Biomedical Informatics, and Department of Neuroscience, University of Kentucky, Lexington, KY, 40536, USA.
Rui ChangDepartment of Neurology, University of Arizona, Tucson, AZ, 85721, USA. ruichang@email.arizona.edu.
John D FryerDepartment of Neuroscience, Mayo Clinic, Scottsdale, AZ, 85259, USA. fryer.john@mayo.edu.ORCID 0000-0003-3390-2994
WinnMed · USIcahn School of Medicine at Mount Sinai · USUniversity of Arizona · USMayo Clinic in Arizona · USUniversity of Kentucky · US

Funding

Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's DiseaseU01AG046170 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI EHRLICH, MICHELLE E, GANDY, SAMUEL E. · 2013 to 2022
$26.0M
Project 3: Neuropathology of the multi-proteinopathy of c9FTD/ALS.P01NS084974 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2014 to 2024
$17.6M
Utilization of proteomics and lipidomics to identify modifiers of LBDU54NS110435 · NINDS · MAYO CLINIC JACKSONVILLE · PI MCLEAN, PAMELA J · 2019 to 2023
$14.5M
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal EndophenotypeR01AG057931 · NIA · UNIVERSITY OF ARIZONA · PI BRINTON, ROBERTA EILEEN, CHANG, RUI · 2018 to 2022
$6.0M
Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to TreatmentRF1AG059093 · NIA · DUKE UNIVERSITY · PI BRINTON, ROBERTA EILEEN, CHANG, RUI · 2018 to 2018
$5.9M
Novel Network Biology Approaches to Reposition FDA-approved Drugs for Alzheimer's DiseaseR01AG068030 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BRENNAND, KRISTEN JENNIFER, CAI, DONGMING · 2020 to 2024
$4.2M
Novel genetic modifiers of C9orf72 and Tau toxicityRF1AG062077 · NIA · MAYO CLINIC ARIZONA · PI FRYER, JOHN DAVID, PETRUCELLI, LEONARD · 2019 to 2019
$4.0M
Microglial apoE in neuroinflammation and Alzheimer's diseaseRF1AG062110 · NIA · MAYO CLINIC ARIZONA · PI FRYER, JOHN DAVID · 2019 to 2019
$4.0M
Using long-range technologies as a multi-omic approach to understand Alzheimer’s disease in brain tissueR01AG068331 · NIA · UNIVERSITY OF KENTUCKY · PI EBBERT, MARK T W · 2020 to 2024
$3.0M
Understanding how structural mutations and individual RNA isoformsare involved in human health and diseaseR35GM138636 · NIGMS · UNIVERSITY OF KENTUCKY · PI Mark T W Ebbert · 2020 to 2026
$2.9M
Building Novel Predictive Networks for high-throughput, in-silico Key Driver Prioritization to Enhance Drug Target Discovery in AMP-AD and M2OVE-ADRF1AG057457 · NIA · UNIVERSITY OF ARIZONA · PI BRADSHAW, ELIZABETH M, CHANG, RUI · 2017 to 2019
$2.3M
The role of Clusterin in cerebral amyloid angiopathyR01NS094137 · NINDS · MAYO CLINIC JACKSONVILLE · PI FRYER, JOHN DAVID · 2015 to 2019
$1.7M
NIA NIH HHS R01 AG057931NIA NIH HHS R01 AG068030NIA NIH HHS R01 AG068331NIA NIH HHS R03 AG049992NIA NIH HHS R21 AG047327NIA NIH HHS R21 AG057997NIA NIH HHS R56 AG062556NIA NIH HHS R56 AG062620NIA NIH HHS RF1 AG057457NIA NIH HHS RF1 AG059093NIA NIH HHS RF1 AG062077NIA NIH HHS RF1 AG062110NIA NIH HHS U01 AG046170NIGMS NIH HHS R35 GM138636NINDS NIH HHS P01 NS084974NINDS NIH HHS R01 NS094137NINDS NIH HHS U54 NS110435
6 · The paper itself

Abstract

backgroundMicroglia, the resident immune cells of the brain, play a critical role in numerous diseases, but are a minority cell type and difficult to genetically manipulate in vivo with viral vectors and other approaches. Primary cultures allow a more controlled setting to investigate these cells, but morphological and transcriptional changes upon removal from their normal brain environment raise many caveats from in vitro studies.

methodsTo investigate whether cultured microglia recapitulate in vivo microglial signatures, we used single-cell RNA sequencing (scRNAseq) to compare microglia freshly isolated from the brain to primary microglial cultures. We performed cell population discovery, differential expression analysis, and gene co-expression module analysis to compare signatures between in vitro and in vivo microglia. We constructed causal predictive network models of transcriptional regulators from the scRNAseq data and identified a set of potential key drivers of the cultured phenotype. To validate this network analysis, we knocked down two of these key drivers, C1qc and Prdx1, in primary cultured microglia and quantified changes in microglial activation markers.

resultsWe found that, although often assumed to be a relatively homogenous population of cells in culture, in vitro microglia are a highly heterogeneous population consisting of distinct subpopulations of cells with transcriptional profiles reminiscent of macrophages and monocytes, and are marked by transcriptional programs active in neurodegeneration and other disease states. We found that microglia in vitro presented transcriptional activation of a set of "culture shock genes" not found in freshly isolated microglia, characterized by strong upregulation of disease-associated genes including Apoe, Lyz2, and Spp1, and downregulation of homeostatic microglial markers, including Cx3cr1, P2ry12, and Tmem119. Finally, we found that cultured microglia prominently alter their transcriptional machinery modulated by key drivers from the homeostatic to activated phenotype. Knockdown of one of these drivers, C1qc, resulted in downregulation of microglial activation genes Lpl, Lyz2, and Ccl4.

conclusionsOverall, our data suggest that when removed from their in vivo home environment, microglia suffer a severe case of "culture shock", drastically modulating their transcriptional regulatory network state from homeostatic to activated through upregulation of modules of culture-specific genes. Consequently, cultured microglia behave as a disparate cell type that does not recapitulate the homeostatic signatures of microglia in vivo. Finally, our predictive network model discovered potential key drivers that may convert activated microglia back to their homeostatic state, allowing for more accurate representation of in vivo states in culture. Knockdown of key driver C1qc partially attenuated microglial activation in vitro, despite C1qc being only weakly upregulated in culture. This suggests that even genes that are not strongly differentially expressed across treatments or preparations may drive downstream transcriptional changes in culture.

Indexed as

BrainMicrogliaDown-RegulationHomeostasisMacrophagesCausal network analysisIn vitro cultureMicrogliaSingle cell RNA sequencing

Identifiers

PMID35346293
PMCPMC8962153
OpenAlexW4220862875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.